A shortened drug regimen to treat tuberculosis (TB) works faster and is more effective than the current standard treatment in patients with drug-susceptible and multidrug resistant (MDR) TB, according to a study by researchers from South Africa, Tanzania, and the United States (Dawson R et al. Lancet. doi:10.1016/S0140-6736(14)62002-X [published online March 17, 2015]).
In this phase 2b trial, the investigators assessed the efficacy, tolerability, and safety of a 3-drug combination regimen consisting of moxifloxacin, pretomanid, and pyrazinamide in patients with both drug-susceptible and MDR pulmonary TB. Moxifloxacin and pretomanid, unlike pyrazinamide, are not yet licensed for use against TB. In the 8-week study that was carried out at 8 sites in South Africa and Tanzania, the researchers randomly assigned 207 patients with drug-susceptible TB (roughly 1:1:1) to receive the 3-drug combination regimen with either 100 or 200 mg of pretomanid (referred to as MPa100Z or MPa200Z, respectively) or the current standard treatment (isoniazid, rifampicin, pyrazinamide, and ethambutol). They also nonrandomly assigned 26 patients with MDR TB to receive the MPa200Z regimen.
Friedrich M. Study Evaluates Shortened TB Drug Regimen. JAMA. 2015;313(19):1897. doi:10.1001/jama.2015.4212
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: